Descartes-25 in Relapsed/Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and
preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting
a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple
Myeloma.